United States Glioblastoma Multiforme Market to hit US$ 2.04 Billion by 2033 | Major Market Players - Genentech (Roche), Pfizer, Amgen

As per DataM intelligence research report "The global glioblastoma multiforme market reached US$ 2.68 billion in 2023, with a rise to US$ 2.92 billion in 2024, and is expected to reach US$ 6.81 billion by 2033, growing at a CAGR of 9.6% during the forecast period 2025-2033."

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/glioblastoma-multiforme-market?prasad

United States: Recent Glioblastoma Multiforme Developments

✅ In January 2026, Novocure expanded clinical momentum for its Optune Tumor Treating Fields platform in glioblastoma multiforme through continued post-approval studies and real-world data generation. The company focused on optimizing treatment duration and patient adherence in newly diagnosed GBM. These efforts aim to strengthen Optune's role alongside standard chemoradiotherapy.

✅ In December 2025, Eli Lilly advanced early-stage clinical evaluation of novel oncology assets with relevance to aggressive solid tumors including glioblastoma multiforme. The company emphasized precision-based approaches targeting tumor microenvironment and resistance pathways. These developments reflect sustained R&D investment in high-mortality brain cancers.

✅ In November 2025, ImmunityBio continued development of its immunotherapy platform for recurrent and treatment-resistant glioblastoma multiforme in the United States. The program focuses on activating innate and adaptive immune responses within the central nervous system. The company is positioning its candidates as adjuncts to existing GBM treatment regimens.

✅ In September 2025, Bristol Myers Squibb supported ongoing clinical research programs evaluating checkpoint inhibitor combinations in glioblastoma multiforme. The studies aim to overcome immune resistance seen in brain tumors through optimized dosing and combination strategies. These initiatives reinforce the company's long-term oncology pipeline strategy.

Japan: Recent Glioblastoma Multiforme Developments

✅ In January 2026, Daiichi Sankyo advanced oncology pipeline research with relevance to high-grade gliomas including glioblastoma multiforme. The company emphasized antibody-drug conjugate platforms designed to improve tumor selectivity. These programs highlight Japan's continued focus on next-generation oncology therapeutics.

✅ In December 2025, Ono Pharmaceutical continued clinical research involvement in immuno-oncology programs applicable to glioblastoma multiforme. The company is evaluating immune modulation strategies that may enhance anti-tumor activity in central nervous system malignancies. This reflects sustained investment in difficult-to-treat cancers.

✅ In November 2025, Sumitomo Pharma progressed CNS-focused oncology research addressing aggressive brain tumors such as glioblastoma multiforme. The company's development efforts target novel molecular pathways associated with tumor growth and resistance. These activities support Japan's expanding neuro-oncology research landscape.

✅ In September 2025, Eisai continued global oncology collaboration efforts relevant to glioblastoma multiforme treatment development. The company is leveraging its neuroscience expertise to explore therapies that cross the blood-brain barrier. Eisai's approach integrates oncology and CNS research capabilities.

Glioblastoma multiforme Market: Drivers

The glioblastoma multiforme (GBM) market is experiencing growth due to rising incidence of aggressive brain tumors and increasing awareness of early diagnosis. Expanding research in molecular and genetic profiling supports development of targeted therapies and personalized treatment strategies. Growth in oncology healthcare infrastructure and the adoption of advanced imaging technologies enhance patient outcomes. Rising investment in clinical trials for novel drugs, immunotherapies, and combination treatments is further driving market expansion. The increasing global burden of neurological disorders and cancer is accelerating demand for effective interventions. Awareness campaigns, improved screening, and focus on quality-of-life management are contributing to adoption. Collaborations among biotech firms, research institutes, and healthcare providers are strengthening market dynamics.

Technological advancements are reshaping GBM treatment and management. Innovations in immunotherapy, targeted small-molecule drugs, CAR-T cell therapy, and precision radiation techniques are improving survival rates. Development of advanced surgical tools, intraoperative imaging, and nanomedicine is enhancing treatment accuracy and reducing recurrence. AI-driven diagnostics, biomarkers, and genomic sequencing are enabling personalized treatment plans. Expansion of clinical research and adoption of patient-centric therapies supports better outcomes. Moreover, global initiatives for brain tumor awareness and funding for innovative drug pipelines are fueling growth. With ongoing breakthroughs and growing patient demand, the GBM market is poised for significant expansion.

Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/glioblastoma-multiforme-market?prasad

Glioblastoma multiforme Market: Major Players

Genentech (Roche), Pfizer, Amgen, Merck & Co., VBI Vaccines, and Starlight Therapeutics, all actively advancing GBM therapies.

Segment Covered in the Glioblastoma multiforme Market:

➥ By Product Type: Radiation Therapy, Chemotherapy, Immunotherapy, Surgery, Others
➥ By Drugs: Temozolomide, Lomustine, Bevacizumab, Others
➥ By Distribution Channel: Hospitals, Specialty Clinics, Others

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=glioblastoma-multiforme-market

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Most Frequently Asked Questions in the Glioblastoma multiforme Market Research Industry:

➠ Who leads the Glioblastoma multiforme industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Glioblastoma multiforme market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Glioblastoma multiforme market growth?
➠ What are the dominant sales and distribution strategies in the Glioblastoma multiforme industry?

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.